Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.51 - $16.96
Previous CloseN/A
Volume220.82K
Average Volume (3M)169.61K
Market Cap
$33.52M
Enterprise Value$148.44M
Total Cash (Recent Filing)$69.94M
Total Debt (Recent Filing)$186.70M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 11, 2025EPS Estimate
-4.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding8,639,904
10 Day Avg. Volume136,664
30 Day Avg. Volume169,611
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.43
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.09
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$23.25Price Target Upside485.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentNew data from the Phase II XPORT-MF-035 study showed signs of spleen volume reduction and symptom improvement in pretreated myelofibrosis patients, indicating promising clinical progress.
Regulatory ApprovalsReimbursement approvals were received in the UK, Italy, France, China, and South Korea, highlighting positive market expansion.
Bears Say
Capital And FinancingCurrent cash runway and recent failure to raise capital raise significant concern, affecting financial stability.
Clinical TrialsPotential risks include negative clinical data, slower-than-expected clinical development timelines, and setbacks in later-stage clinical studies, which could impact the company's growth prospects.
Financial PerformanceKPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter, raising concerns about revenue generation.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $16.96 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $33.52M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on May 12, 2025. The company reported -$2.77 earnings per share for the quarter, beating the consensus estimate of -$4.419 by $1.649.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -4.08.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 8,639,904 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$2.77 in its last earnings report, beating expectations of -$4.419. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.25 (485.64% Upside)
$23.25 (485.64% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.01%
12-Months-Change
Fundamentals
Return on Equity
41.08%
Trailing 12-Months
Asset Growth
-37.54%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and potential market opportunities, particularly in myelofibrosis, but was tempered by financial challenges related to product returns and cash runway concerns. The data on selinexor is promising, but the financials indicate areas of concern that need addressing.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$23.25
▲(485.64% Upside)
Technical Analysis
X4 Pharmaceuticals
―
Connect Biopharma Holdings
―
Werewolf Therapeutics
―
PepGen Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
9.42% Insiders
34.90% Mutual Funds
<0.01% Other Institutional Investors
51.47% Public Companies and
Individual Investors